PLOD2

Across TCGA pan-cancer cohorts, PLOD2 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PLOD2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PLOD2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLOD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where PLOD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.705	0.958	<.001	123	view →
PDAC	DFS	Quartile	All	0.234	0.463	.004	40	view →
LUAD	OS	Median	III,IV	0.210	0.684	.003	22	view →
COAD	DFS	Quartile	II,III,IV	0.791	1.000	.026	18	view →
GBM	DFS	Tertile	All	0.586	0.864	.002	14	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.447	.018	8	view →
LSCC	DFS	Median	All	0.602	0.805	.006	4	view →
HNSC	OS	Median	All	0.642	0.797	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PLOD2–CCRCC (OS)

Open the CCRCC breakdown →